01576nas a2200445   4500000000100000000000100001000000100002008004100003653001100044653000900055653005500064653002600119653002500145653002800170653003600198653003200234653003200266653002000298653003000318653002300348653007900371653005500450653002700505653008400532653004700616653003900663653006900702653001200771653007800783100001800861700001400879700001500893700001600908700001800924700001600942245014000958250001501098300001001113490000701123       2023                            d10aHumans10aMale10a*Muscular Dystrophy, Duchenne/epidemiology/therapy10aRetrospective Studies10aLongitudinal Studies10aAdrenal Cortex Hormones10a*Cardiomyopathies/complications10aUnited Kingdom/epidemiology10aDuchenne muscular dystrophy10aEconomic models10aElectronic Health Records10astatistical models10afees from Duchenne UK. Michela Guglieri has received research funding from10aSarepta, PTC, Muscular Dystrophy UK, NIH and H202010ais (or has been) chief10ainvestigator/principal investigator for clinical trials of Pfizer, Italfarmaco,10aSanthera, Roche, ReveraGen, Dynacure, Dyne10ais a member of Advisory boards for10aPfizer, NS Pharma, Dyne (honoraria through Newcastle University)10aand has10areceived speaker honoraria from Sarepta, Italfarmaco, Novartis and Roche.1 aJ. Broomfield1 aK. Abrams1 aN. Latimer1 aM. Guglieri1 aM. Rutherford1 aM. Crowther00aNatural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink  a2023/11/14  ae33310 v13